AU2010290844B2 - Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof - Google Patents

Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof Download PDF

Info

Publication number
AU2010290844B2
AU2010290844B2 AU2010290844A AU2010290844A AU2010290844B2 AU 2010290844 B2 AU2010290844 B2 AU 2010290844B2 AU 2010290844 A AU2010290844 A AU 2010290844A AU 2010290844 A AU2010290844 A AU 2010290844A AU 2010290844 B2 AU2010290844 B2 AU 2010290844B2
Authority
AU
Australia
Prior art keywords
ser
tyr
seq
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010290844A
Other languages
English (en)
Other versions
AU2010290844A1 (en
Inventor
Yaakov Naparstek
Shira Yair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROTAB Ltd
Original Assignee
PROTAB Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROTAB Ltd filed Critical PROTAB Ltd
Publication of AU2010290844A1 publication Critical patent/AU2010290844A1/en
Application granted granted Critical
Publication of AU2010290844B2 publication Critical patent/AU2010290844B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010290844A 2009-09-06 2010-09-06 Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof Ceased AU2010290844B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24021809P 2009-09-06 2009-09-06
US61/240,218 2009-09-06
PCT/IL2010/000731 WO2011027349A1 (en) 2009-09-06 2010-09-06 Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof

Publications (2)

Publication Number Publication Date
AU2010290844A1 AU2010290844A1 (en) 2012-03-15
AU2010290844B2 true AU2010290844B2 (en) 2015-04-09

Family

ID=43648941

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010290844A Ceased AU2010290844B2 (en) 2009-09-06 2010-09-06 Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof

Country Status (12)

Country Link
US (3) US8680241B2 (cg-RX-API-DMAC7.html)
EP (2) EP3366308A1 (cg-RX-API-DMAC7.html)
JP (1) JP5781514B2 (cg-RX-API-DMAC7.html)
KR (1) KR101831229B1 (cg-RX-API-DMAC7.html)
CN (1) CN102740877B (cg-RX-API-DMAC7.html)
AU (1) AU2010290844B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012004983A2 (cg-RX-API-DMAC7.html)
CA (1) CA2772567A1 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN02869A (cg-RX-API-DMAC7.html)
MX (1) MX2012002768A (cg-RX-API-DMAC7.html)
RU (1) RU2596925C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011027349A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940683B2 (en) 2006-08-10 2015-01-27 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
CA2960445A1 (en) * 2014-10-24 2016-04-28 F.Hoffmann-La Roche Ag Vh-vl-interdomain angle based antibody humanization
WO2016116948A1 (en) 2015-01-22 2016-07-28 Ram Isanaka Peptide for treating inflammatory diseases
EP3320099B1 (en) * 2015-07-09 2023-09-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Lentiviral vector expressing membrane-anchored or secreted antibody
US12296085B2 (en) * 2016-03-31 2025-05-13 ImMutriX Therapeutics, Inc. Method for extracorporeal treatment of preeclampsia and related disorders
SG11202101038SA (en) * 2018-08-01 2021-02-25 Imcheck Therapeutics Sas Anti-btn3a antibodies and their use in treating cancer or infectious disorders
WO2025155809A2 (en) * 2024-01-18 2025-07-24 Nextcure, Inc. Compositions and methods for modulating vstm-1 mediated signal transduction
WO2025231127A1 (en) * 2024-05-02 2025-11-06 The Regents Of The University Of California Compositions and methods for intracellular antigen targeting with antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123535A1 (en) * 1998-11-05 2005-06-09 Hadasit Medical Research Services & Development Ltd. Novel amino acid sequences, DNA encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
US20080019979A1 (en) * 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
ATE315577T1 (de) * 1998-11-05 2006-02-15 Hadasit Med Res Service Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
AU2002360857A1 (en) * 2001-12-31 2003-07-24 L.A.S. Trust, Ein 02/6105365 Recreational vehicle
EP1619521A1 (en) 2004-07-22 2006-01-25 IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. Capacitive transmitter electrode
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
DK1844074T3 (da) 2005-02-03 2013-07-15 Antitope Ltd Humane antistoffer og proteiner
EP1989544B1 (en) 2006-03-02 2011-06-22 Antitope Limited T cell assays
WO2008114733A1 (ja) * 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP2500362A3 (en) * 2007-11-13 2012-10-24 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against TL1A
WO2010113148A1 (en) 2009-03-30 2010-10-07 Protab Ltd. Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation
CA2841416A1 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123535A1 (en) * 1998-11-05 2005-06-09 Hadasit Medical Research Services & Development Ltd. Novel amino acid sequences, DNA encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
US20080019979A1 (en) * 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods

Also Published As

Publication number Publication date
MX2012002768A (es) 2012-06-28
JP2013503852A (ja) 2013-02-04
US20120156201A1 (en) 2012-06-21
CN102740877B (zh) 2015-01-14
WO2011027349A1 (en) 2011-03-10
JP5781514B2 (ja) 2015-09-24
EP3366308A1 (en) 2018-08-29
AU2010290844A1 (en) 2012-03-15
KR101831229B1 (ko) 2018-02-22
US20170218056A1 (en) 2017-08-03
US8680241B2 (en) 2014-03-25
EP2475383A1 (en) 2012-07-18
CA2772567A1 (en) 2011-03-10
KR20120060224A (ko) 2012-06-11
CN102740877A (zh) 2012-10-17
BR112012004983A2 (pt) 2021-02-23
RU2596925C2 (ru) 2016-09-10
EP2475383A4 (en) 2013-07-17
IN2012DN02869A (cg-RX-API-DMAC7.html) 2015-07-24
US20140170138A1 (en) 2014-06-19
RU2012106891A (ru) 2013-10-27

Similar Documents

Publication Publication Date Title
US12234281B2 (en) Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
US20170218056A1 (en) Humanized antibodies specific for hsp65-derived peptide-6, methods and uses thereof
US20240368263A1 (en) Optimized anti-tl1a antibodies
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
RU2687209C1 (ru) Собачьи антитела с модифицированными последовательностями ch2-ch3
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
RU2725950C1 (ru) Антитела против белка-1 запрограммированной клеточной смерти (pd-1) и их применение
JP7753264B2 (ja) ソルチリンを認識する抗体
EP2751139A1 (en) Caninised tumour necrosis factor antibodies and methods of using the same
EP4660205A1 (en) Multiple antibodies against human il-36r and/or human il-1r3, and uses thereof
EP3283518B1 (en) Anti-plasmodium parasite antibodies
WO2022256739A2 (en) Antibody specific for bcl-6 and methods of use
JP7202011B2 (ja) 抗ｒａｍｐ２抗体
WO2025146161A1 (en) Antibody, antigen-binding fragment and medical use thereof
TW202542202A (zh) 抗體、抗原結合片段及其醫療用途
WO2013172379A1 (ja) 新規抗体及びその用途
HK40042163A (en) Optimized anti-tl1a antibodies
EA044647B1 (ru) Терапия транстиретинового (ттр) амилоидоза антителами, а также антитела, полученные от человека для указанной терапии

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired